Acquisition completed
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, has completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court.
“We are pleased to reach this important milestone for the Company, its employees, shareholders and the patients we serve,” said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. “Our new Allergan colleagues should be commended for all their efforts, along with those of our own employees, to achieve this turning point. The new AbbVie will be a well-diversified leader in many important therapeutic categories, with both on-market and pipeline assets, and our financial strength will allow us to continue to invest in innovative science and continue to serve unmet medical needs of patients that rely upon us.”
https://news.abbvie.com/
Latest Articles
Towards a Unified IOL Classification
The new IOL functional classification needs a strong and unified effort from surgeons, societies, and industry.
The 5 Ws of Post-Presbyopic IOL Enhancement
Fine-tuning refractive outcomes to meet patient expectations.
AI Shows Promise for Meibography Grading
Study demonstrates accuracy in detecting abnormalities and subtle changes in meibomian glands.
Are There Differences Between Male and Female Eyes?
TOGA Session panel underlined the need for more studies on gender differences.
Simulating Laser Vision Correction Outcomes
Individualised planning models could reduce ectasia risk and improve outcomes.
Need to Know: Aberrations, Aberrometry, and Aberropia
Understanding the nomenclature and techniques.
Organising for Success
Professional and personal goals drive practice ownership and operational choices.
Update on Astigmatism Analysis
Is Frugal Innovation Possible in Ophthalmology?
Improving access through financially and environmentally sustainable innovation.